Correlates of Immunity to Group A Streptococcus: a Pathway to Vaccine Development

Overview

Journal NPJ Vaccines

Date 2023 Jan 17

PMID 36650164

Authors

Hannah Frost

Jean-Louis Excler

Shiranee Sriskandan

Alma Fulurija

Affiliations

Soon will be listed here.

Abstract

Understanding immunity in humans to Group A Streptococcus (Strep A) is critical for the development of successful vaccines to prevent the morbidity and mortality attributed to Strep A infections. Despite decades of effort, no licensed vaccine against Strep A exists and immune correlates of protection are lacking; a major impediment to vaccine development. In the absence of a vaccine, we can take cues from the development of natural immunity to Strep A in humans to identify immune correlates of protection. The age stratification of incidence of acute Strep A infections, peaking in young children and waning in early adulthood, coincides with the development of specific immune responses. Therefore, understanding the immune mechanisms involved in natural protection from acute Strep A infection is critical to identifying immune correlates to inform vaccine development. This perspective summarises the findings from natural infection studies, existing assays of immunity to Strep A, and highlights the gaps in knowledge to guide the development of Strep A vaccines and associated correlates of protection.

Citing Articles

Dissecting the properties of circulating IgG against streptococcal pathogens through a combined systems antigenomics-serology workflow.

Gomez Toledo A, Chowdhury S, Hjortswang E, Sorrentino J, Lewis N, Blackberg A Nat Commun. 2025; 16(1):1942.

PMID: 39994218 PMC: 11850916. DOI: 10.1038/s41467-025-57170-5.

From natural defenders to therapeutic warriors: NK cells in HIV immunotherapy.

Laeremans T, Janssens A, Aerts J Immunotherapy. 2025; 17(2):133-145.

PMID: 39905963 PMC: 11901454. DOI: 10.1080/1750743X.2025.2460965.

Rift Valley Fever in Rwanda Is Urging for Enhancing Global Health Security Through Multisectoral One Health Strategy.

Muvunyi C, Ngabonziza J, Siddig E, Ahmed A Microorganisms. 2025; 13(1).

PMID: 39858859 PMC: 11768005. DOI: 10.3390/microorganisms13010091.

S6P mutation in Delta and Omicron variant spike protein significantly enhances the efficacy of mRNA COVID-19 vaccines.

Bong Y, Brown D, Chung E, Ananthaswamy N, Chen R, Lewoczko E Front Immunol. 2025; 15():1495561.

PMID: 39830514 PMC: 11739128. DOI: 10.3389/fimmu.2024.1495561.

Streptococcus pyogenes pharyngitis elicits diverse antibody responses to key vaccine antigens influenced by the imprint of past infections.

Osowicki J, Frost H, Azzopardi K, Whitcombe A, McGregor R, Carlton L Nat Commun. 2024; 15(1):10506.

PMID: 39627204 PMC: 11614873. DOI: 10.1038/s41467-024-54665-5.

References

Salvadori L, Blake M, McCarty M, Tai J, Zabriskie J . Group A streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capabilities of the antibodies. J Infect Dis. 1995; 171(3):593-600. DOI: 10.1093/infdis/171.3.593. View

Moore H, Miller K, Carapetis J, Van Beneden C . Harmonizing Surveillance Methodologies for Group A Streptococcal Diseases. Open Forum Infect Dis. 2022; 9(Suppl 1):S1-S4. PMC: 9474938. DOI: 10.1093/ofid/ofac210. View

Quinn R, Vander Zwaag R, LOWRY P . Acquisition of group A streptococcal M protein antibodies. Pediatr Infect Dis. 1985; 4(4):374-8. DOI: 10.1097/00006454-198507000-00008. View

Mills J, Ghosh P . Nonimmune antibody interactions of Group A Streptococcus M and M-like proteins. PLoS Pathog. 2021; 17(2):e1009248. PMC: 7906336. DOI: 10.1371/journal.ppat.1009248. View

Jaggi P, Dale J, Chiang E, Beniwal P, Kabat W, Shulman S . Age-associated differences in prevalence of group A streptococcal type-specific M antibodies in children. Eur J Pediatr. 2008; 168(6):679-83. DOI: 10.1007/s00431-008-0819-6. View

Tan L, Reglinski M, Teo D, Reza N, Lamb L, Nageshwaran V . Vaccine-induced, but not natural immunity, against the Streptococcal inhibitor of complement protects against invasive disease. NPJ Vaccines. 2021; 6(1):62. PMC: 8062509. DOI: 10.1038/s41541-021-00326-3. View

Excler J, Kim J . Accelerating the development of a group A Streptococcus vaccine: an urgent public health need. Clin Exp Vaccine Res. 2016; 5(2):101-7. PMC: 4969273. DOI: 10.7774/cevr.2016.5.2.101. View

Polly S, Waldman R, High P, WITTNER M, DORFMAN A . Protective studies with a group A streptococcal M protein vaccine. II. Challange of volenteers after local immunization in the upper respiratory tract. J Infect Dis. 1975; 131(3):217-24. DOI: 10.1093/infdis/131.3.217. View

. FAILURE of type specific Streptococcus pyogenes vaccine to prevent respiratory infections. U S Nav Med Bull. 2010; 46:709-18. View

10.

Pastural E, McNeil S, MacKinnon-Cameron D, Ye L, Langley J, Stewart R . Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study. Vaccine. 2019; 38(6):1384-1392. DOI: 10.1016/j.vaccine.2019.12.005. View

11.

Okamoto S, Tamura Y, Terao Y, Hamada S, Kawabata S . Systemic immunization with streptococcal immunoglobulin-binding protein Sib 35 induces protective immunity against group: a Streptococcus challenge in mice. Vaccine. 2005; 23(40):4852-9. DOI: 10.1016/j.vaccine.2005.02.035. View

12.

Reglinski M, Gierula M, Lynskey N, Edwards R, Sriskandan S . Identification of the Streptococcus pyogenes surface antigens recognised by pooled human immunoglobulin. Sci Rep. 2015; 5:15825. PMC: 4623672. DOI: 10.1038/srep15825. View

13.

Reglinski M, Lynskey N, Sriskandan S . Modification of the classical Lancefield assay of group A streptococcal killing to reduce inter-donor variation. J Microbiol Methods. 2016; 124:69-71. PMC: 4838658. DOI: 10.1016/j.mimet.2016.03.015. View

14.

Henningham A, Chiarot E, Gillen C, Cole J, Rohde M, Fulde M . Conserved anchorless surface proteins as group A streptococcal vaccine candidates. J Mol Med (Berl). 2012; 90(10):1197-207. DOI: 10.1007/s00109-012-0897-9. View

15.

Beaton A, Kamalembo F, Dale J, Kado J, Karthikeyan G, Kazi D . The American Heart Association's Call to Action for Reducing the Global Burden of Rheumatic Heart Disease: A Policy Statement From the American Heart Association. Circulation. 2020; 142(20):e358-e368. DOI: 10.1161/CIR.0000000000000922. View

16.

Basma H, Norrby-Teglund A, McGeer A, Low D, Dale J, Schwartz B . Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections. Infect Immun. 1998; 66(5):2279-83. PMC: 108192. DOI: 10.1128/IAI.66.5.2279-2283.1998. View

17.

Jones S, Moreland N, Zancolli M, Raynes J, Loh J, Smeesters P . Development of an opsonophagocytic killing assay for group a streptococcus. Vaccine. 2018; 36(26):3756-3763. DOI: 10.1016/j.vaccine.2018.05.056. View

18.

Allhorn M, Olsen A, Collin M . EndoS from Streptococcus pyogenes is hydrolyzed by the cysteine proteinase SpeB and requires glutamic acid 235 and tryptophans for IgG glycan-hydrolyzing activity. BMC Microbiol. 2008; 8:3. PMC: 2266755. DOI: 10.1186/1471-2180-8-3. View

19.

Bensi G, Mora M, Tuscano G, Biagini M, Chiarot E, Bombaci M . Multi high-throughput approach for highly selective identification of vaccine candidates: the Group A Streptococcus case. Mol Cell Proteomics. 2012; 11(6):M111.015693. PMC: 3433891. DOI: 10.1074/mcp.M111.015693. View

20.

Lamagni T, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B . Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol. 2008; 46(7):2359-67. PMC: 2446932. DOI: 10.1128/JCM.00422-08. View